The Biotechnology Industry Organization (BIO) will be holding its fifth annual IP & Diagnostics Symposium from 8:15 am to 2:00 pm on September 29, 2017 at the Westin Alexandria in Alexandria, VA. The Symposium review the current patent law landscape and evaluate the impact on both the genetic diagnostics and biopharmaceutical sectors, and also explore new collaborations and regulatory developments. The Symposium will offer the following presentations and sessions:
• Session 1 -- The Walls Are Closing In – The Bleak Future of Claims Reciting Natural ‘Correlations’ and Products of Nature – Dr. Leslie Fischer, Novartis; Hans Sauer, Biotechnology Innovation Organization; and Warren Woessner, Schwegman, Lundberg & Woessner, P.A.
• Session 2 -- Adapting Patent Prosecution Practice for the Next Generation of Life Science Inventions -- Patent Docs author Donald Zuhn of McDonnell Boehnen Hulbert & Berghoff LLP will moderate a panel consisting of June Cohan, Legal Advisor Office of Patent Legal Administration, U.S. Patent and Trademark Office; Benjamin Jackson, Vice President Legal Affairs, Myriad Genetics; and Kwame Mensah, Senior Patent Attorney, Immunooncology IP Lead, AstraZeneca/MedImmune.
• Session 3 -- The Regulatory Environment for Diagnostic Tests and Companion Diagnostics -- Ellen Flannery, Covington; and Esther Scherb, Covington.
• Session 4 (Working Luncheon) -- Life Sciences Valuations - Where IP Fits In -- Dr. Patrick Frei, CEO, Venture Valuation; and Ulrich Thiele, Director, European Patent Office.
An agenda for the Symposium, including a list of speakers, moderators, and panelists can be obtained here.
The registration fee for the Symposium is $70-90 (service provider rates), $40-50 (in-house counsel at R&D company rates), or $0 (academic, government & non-profit association rates). Those interested in registering for the Symposium, can do so here.
Comments